Under construction – not a live service
Sign in
Taking people in CzechiaNo phase

Electroconvulsive Therapy With Added Magnetic Stimulation for Depression That Has Not Responded to Treatment

Tests electroconvulsive therapy plus magnetic stimulation in adults with depression resistant to treatment.

Plain-language title generated from the registry record
Registry title: Electroconvulsive Therapy Augmented With Transcranial Magnetic Stimulation for Treatment Resistant Depression

Key facts

Where
Prague, CzechiaSee the site

Where in Czechia

  • General University Hospital, Psychiatry departmentPrague, CzechiaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Charles University, Czech Republic
Trial code
NCT07324070
Record updated
7 January 2026
Original description
The RTMSECT2 study was design to compare the application of electroconvulsive therapy augmented by transcranial magnetic stimulation. Subject will be compared both within groups and in group using psychometric scales and different deliver energyRead full original descriptionShow less

New Methods Electroconvulsive Therapy Augmentation

The RTMSECT2 study was design to compare the application of electroconvulsive therapy augmented by transcranial magnetic stimulation. Subject will be compared both within groups and in group using psychometric scales and different deliver energy

Inclusion: Age equal to 18 or higher; MADRS (Montgomery-Asberg Depression Scale) qual or higher than 20; Major depressive disorder according to ICD 10.

Exclusion: Other axis 1 disorder (for example schizofrenia, addiction, etc.); No dementia; Psychotic disease or symptoms; Any neurological disease (for example epilepsy, etc.); somatic condition which contraindicates ECT; ECT in the last 3 months; TMS in the last 3 months; Ppregnancy or lactation; Participation in another clinical trial within the last 30 days.

ClinicalTrials.gov NCT07324070